Dofetilide: a new class III antiarrhythmic agent

  title={Dofetilide: a new class III antiarrhythmic agent},
  author={Henri Roukoz and Walid I. Saliba},
  journal={Expert Review of Cardiovascular Therapy},
  pages={19 - 9}
  • H. RoukozW. Saliba
  • Published 1 January 2007
  • Medicine
  • Expert Review of Cardiovascular Therapy
Dofetilide is a relatively new class III antiarrhythmic agent that selectively blocks the rapid component of the cardiac ion channel delayed rectifier current. This results in an increase in the action potential duration and effective refractory period of the myocyte, thereby terminating reentrant tachyarrhythmias and preventing their re-induction. Oral dofetilide is effective in the conversion of atrial fibrillation and flutter to sinus rhythm and in the maintenance of sinus rhythm after… 

Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.

The main new generation class III drugs are: dofetilide, dronedarone, azimilide, and ibutilide, which are the gold standard in the prevention of recurrence of atrial fibrillation and flutter.

Newer Antiarrhythmic Agents for Atrial Fibrillation: Shall we Eventually do away with Proarrhythmia?

Future antiarrhythmic agents will probably be atrial-selective blocking agents without affecting repolarization in the ventricular myocardium and thus avoid ventricular proarrhythmics with its attendant life-threatening consequences.

Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.

D should be considered a pharmacologic alternative when adult patients with CHD develop AT but needs close monitoring for potential ventricular pro-arrhythmia.

Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option

The DOxapram Conversion TO Sinus rhythm (DOCTOS)-Trial will reveal whether doxaprams, a potent TASK-1 inhibitor, can be used for acute cardioversion of persistent and paroxysmal AF in patients, potentially leading to a new treatment option for AF.

Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter

Dofetilide is more effective in patients with persistent than in those with paroxysmal AF/AFL, and short-term response does not necessarily predict long-term efficacy.

Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin

This study demonstrates synergistic antiarrhythmic benefits of combined block of IKur and INa, as well as those of INa and combined multi K+-current block of acacetin, without significant alterations of ventricular repolarization and QT intervals.

Dofetilide-Induced Microvolt T-Wave Alternans

In healthy subjects, dofetilide increases occurrence and levels (6 times baseline value on average) of TWA in the hours following its administration, and inhealthy subjects, this phenomenon is associated to malignant ventricular arrhythmias.

Simultaneous Determination of Dofetilide and Amlodipine in Plasma by HPLC

A unique sensitive HPLC assay able to quantify both drugs simultaneously was required to evaluate the possible pharmacokinetic interaction between amlodipine and dofetilide and showed good reproducibility with coefficients of variation less than 10% for all the analytes.



Azimilide dihydrochloride, a novel antiarrhythmic agent.

Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.

The results imply that the suppression of the development and maintenance of reentrant arrhythmias may result from the lengthening effect of dofetilide on the refractoriness and the consequent elimination of the excitable gap at the critical part of theReentrant loop.

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.

Intravenous dofetilide is effective in acute termination of AF and AFL of medium duration, with a particularly high efficacy rate in AFL, and a small but serious risk of proarrhythmia must be anticipated.

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

In patients with congestive heart failure and reduced left ventricular function, dofetilide was effective in converting atrial fibrillation, preventing its recurrence, and reducing the risk of hospitalization for worsening heart failure.

Atrial fibrillation and atrial flutter.

The epidemiology, pathophysiology, diagnosis, evaluation, and treatment of atrial fibrillation (AF) and atrial flutter (AFl) are reviewed, and recent developments and controversies in the approach to